Hot Longevity Mandate: Europe-Based VC

6 Jul

The fund was founded in 2009 and is based in Paris, France. The firm currently manages three Biofunds, the newest of which closed in 2020 and focuses on investments in Europe based therapeutics and medical innovation. The fund invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The fund invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The fund prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: